Structure via PubChem · Public domain (PubChem)
flosequinan
Sign in to saveFlosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.
Chemical data
- Formula
- C11H10FNO2S
- Molecular weight
- 239.27 g/mol
- IUPAC name
- 7-fluoro-1-methyl-3-methylsulfinylquinolin-4-one
- SMILES
- CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
- InChIKey
- UYGONJYYUKVHDD-UHFFFAOYSA-N
- XLogP
- 1.1
- Polar surface area
- 56.6 Ų
- H-bond donors
- 0
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1992
- Indications
- cardiovascular disease
via ChEMBL · EBI
Research
147 papers- Flosequinan.Lancet (London, England) · 1993
- Pharmacology of flosequinan.American heart journal · 1991
- Flosequinan: Morbidity and Mortality.JACC. Heart failure · 2018
- Flosequinan for chronic heart failure?Drug and therapeutics bulletin · 1993
- Flosequinan in chronic heart failure: how is exercise capacity improved?European journal of clinical pharmacology · 1996
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 239.042
Show 3 more facts
- canonical SMILES
- CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C
- chemical formula
- C₁₁H₁₀FNO₂S
- subject has role
- vasodilator agent
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Flosequinan is a quinolone vasodilator that was discovered and developed by Boots UK and was sold for about a year under the trade name Manoplax. It had been approved in 1992 in the US and UK to treat people with heart failure who could not tolerate ACE inhibitors or digitalis.
Boots initiated a clinical trial called PROFILE to see if the drug could be useful in a wider population. The study was terminated early in 1993 due to increased mortality in the drug arm of the trial; preliminary results were published in a conference abstract by the PI Milton Packer and others, which promised data and analysis would be forthcoming in a future paper, which was finally published in 2017.
Excerpted from Wikipedia’s “flosequinan” article, available under the CC BY-SA 4.0 licence.